Logo Image
|Videos|February 8, 2018

Antimicrobial Stewardship Programs: A Necessary Component of Health Care

Debra Goff, PharmD, FCCP, explains the role that antimicrobial stewardship programs have in the fight against multidrug-resistant infections.

Debra Goff, PharmD, FCCP, infectious disease clinical pharmacist at the Ohio State University Wexner Medical Center, explains the role that antimicrobial stewardship programs have in the fight against multidrug-resistant infections. Dr. Goff paints the picture of looking at a ship and stresses that these programs steer the ship, but everyone needs to help make it work. She also provides a little bit of background on how these programs help inform policy and the responsible use of antibiotics in health care settings, underscoring the fact that they are a “necessary component of health care,” especially since the world is in crisis mode due to the growing threat of resistance.

Related to this article

View more
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Read more
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Read more
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Read more